Shots:
- The P-III trial of Eydenzelt vs Eylea (aflibercept) in diabetic macular edema (DME) patients achieved its 1EP of BCVA improvement at wk.8, demonstrating equivalent efficacy, safety & immunogenicity
- The P-III study of Stoboclo & Osenvelt vs Prolia & Xgeva (denosumab) in patients (n=479) achieved its 1EP, showing equivalent efficacy in lumbar spine bone mineral density (BMD) plus similar PK/PD, safety & immunogenicity
- The P-III trial of Avtozma vs RoAtemra (tocilizumab) in mod. to sev. rheumatoid arthritis patients (n=479), depicted equivalent efficacy based on DAS28-ESR scores at wk.12, as well as a sustained efficacy & a comparable safety for up to wk.52
Ref: Celltrion | Image: Celltrion| Press Release
Related News:- Celltrion’s Omlyclo (CT-P39) Secures the Health Canada’s Approval (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
